Honasa Consumer Limited

Honasa Consumer Limited

Honasa Consumer Limited has closed its trading window for insiders from July 1, 2026, until 48 hours after the submission of unaudited Q2 2026 financial results.

Honasa Consumer Limited

Honasa Consumer Limited (HCL) has announced the acquisition of a 58% majority stake in Fluence Pharma, a science-backed nutraceuticals company specializing in patented Cyclical Nutrition Therapy. This strategic move marks HCL's entry into the high-growth nutraceuticals market, particularly focusing on "inside-out" beauty solutions. HCL will establish a new subsidiary, Honasa Health Private Limited, to scale Fluence's B2C nutrition portfolio. Fluence Pharma reported approximately INR 40 Crore revenue with over 20% EBITDA margin in FY26.

Honasa Consumer Limited

Honasa Consumer Limited has approved the acquisition of a majority 58% equity stake in Fluence Pharma Private Limited for approximately ₹135 Crores enterprise value. Fluence Pharma offers condition-specific OTC supplements under brands like "Hair Fact" and "Skin Fact." This strategic move marks Honasa's entry into the rapidly growing nutraceuticals market, which is valued at over ₹16,000 Crores. The company also announced the incorporation of a wholly-owned subsidiary, Honasa Health Private Limited, to manage its B2C nutraceuticals business. The remaining 42% stake in Fluence Pharma will be acquired in two tranches over the next 5-7 years.